Affinity Life Sciences

Executive Summary

Affinity Life Sciences is a US-based contract development and manufacturing organization (CDMO) founded in 2003, specializing in lyophilization, reagent manufacturing, and immunoassay development for the diagnostics, medical device, and pharmaceutical industries. Operating from a cGMP and ISO 13485 compliant facility in Hackensack, New Jersey, the company offers end-to-end services encompassing formulation, assay design, kitting, and distribution. With over two decades of experience, Affinity Life Sciences has established itself as a reliable partner for clients seeking high-quality contract manufacturing and development services in the life sciences sector. The company's expertise in lyophilization and immunoassays positions it well to serve the growing demand for diagnostics and biopharmaceutical products. As a privately held entity, Affinity Life Sciences does not publicly disclose financials, but its sustained operation since 2003 indicates a stable business. The CDMO market is expanding, driven by increased outsourcing by pharmaceutical and diagnostics companies. Affinity Life Sciences is poised to benefit from this trend, particularly in the areas of point-of-care diagnostics and biologic formulations. However, competition from larger CDMOs and the need for continuous investment in capacity and technology present challenges. Overall, the company's niche focus and compliance credentials provide a solid foundation for growth, but its private status limits visibility into near-term performance.

Upcoming Catalysts (preview)

• Q4 2026Capacity Expansion or Facility Upgrade65% success
• 2027Strategic Partnership with Major Diagnostics Company50% success
• Q2 2026FDA Inspection with No Major Findings75% success